Clinical trial
17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond…
NCT00118092 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00118092 |
|---|---|
| Title | 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy |
| Official title | A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients With Hormone-Refractory Metastatic Prostate Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer |
| Intervention type | Drug, Other |
| Interventions | tanespimycin, laboratory biomarker analysis |
| Enrollment | 17 |
| Start date | Jan 1, 2005 |
| Primary completion | May 1, 2006 |
| Completion | Feb 1, 2008 |
| First posted | Jul 11, 2005 |
| Last update posted | Apr 18, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: